查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
干癣治疗的全球市场:产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)
市场调查报告书
商品编码
1110378

干癣治疗的全球市场:产业分析，规模，占有率，成长，趋势，预测(2022年～2031年)

Psoriasis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 200 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球干癣治疗市场相关调查分析，市场促进因素和阻碍因素，COVID-19影响，各市场区隔的分析与预测，各地区分析，企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球干癣治疗市场

第4章 市场概要

  • 简介
    • 医药品分类定义
    • 产业的演进/开发
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球干癣治疗市场分析与预测(2017年～2031年)
    • 市场收益预测
    • 市场规模/出货台数预测
  • 波特的五力分析

第5章 主要洞察

  • 法规情境:各地区/主要国家
  • 开发平台分析
  • 主要的合併和收购
  • COVID-19影响分析

第6章 全球干癣治疗市场分析与预测:各医药品分类

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:各医药品分类(2017年～2031年)
    • TNF抑制剂
    • 白细胞介素抑制剂
    • 维他命D类似体
    • 皮质类固醇
    • 其他
  • 市场魅力分析:各医药品分类

第7章 全球干癣治疗市场分析与预测:各给药途径

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:各给药途径(2017年～2031年)
    • 口服
    • 非口服
    • 局部
  • 市场魅力分析:各给药途径

第8章 全球干癣治疗市场分析与预测:各流通管道

  • 简介和定义
  • 主要调查结果/开发
  • 市场价值预测:各流通管道(2017年～2031年)
    • 院内药局
    • 零售药局
    • 其他
  • 市场魅力分析:各流通管道

第9章 全球干癣治疗市场分析与预测:各地区

  • 主要调查结果
  • 市场价值预测:各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东、非洲
  • 市场魅力分析:各地区

第10章 北美的干癣治疗市场分析与预测

  • 简介
    • 主要调查结果
  • 市场价值预测:各医药品分类(2017年～2031年)
    • TNF抑制剂
    • 白细胞介素抑制剂
    • 维他命D类似体
    • 皮质类固醇
    • 其他
  • 市场价值预测:各给药途径(2017年～2031年)
    • 口服
    • 非口服
    • 局部
  • 市场价值预测:各流通管道(2017年～2031年)
    • 院内药局
    • 零售药局
    • 其他
  • 市场价值预测:各国(2017年～2031年)
    • 美国
    • 加拿大
  • 市场魅力分析
    • 各医药品分类
    • 各给药途径
    • 各流通管道
    • 各国

第11章 欧洲的干癣治疗市场分析与预测

第12章 亚太地区的干癣治疗市场分析与预测

第13章 南美的干癣治疗市场分析与预测

第14章 中东、非洲的干癣治疗市场分析与预测

第15章 竞争情形

  • 市场参与企业 - 竞争矩阵(阶层、各企业规模)
  • 市场占有率分析:各企业(2021年)
  • 企业简介
    • Amgen, Inc.
    • AstraZeneca plc
    • AbbVie, Inc.
    • Eli Lilly and Company
    • Johnson & Johnson
    • Biogen, Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Pfizer, Inc.
    • LEO Pharma A/S
    • 其他企业
Product Code: TMRGL17960

The report provides revenue of the global psoriasis treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global psoriasis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the psoriasis treatment market.

The report delves into the competitive landscape of the global psoriasis treatment market. Key players operating in the global psoriasis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global psoriasis treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriasis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Regulatory Scenario by Region/Key Country
  • 5.2. Pipeline Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Impact Analysis

6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Interleukin Inhibitors
    • 6.3.3. Vitamin D Analogs
    • 6.3.4. Corticosteroids
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriasis Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Psoriasis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Interleukin Inhibitors
    • 10.2.3. Vitamin D Analogs
    • 10.2.4. Corticosteroids
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Psoriasis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Interleukin Inhibitors
    • 11.2.3. Vitamin D Analogs
    • 11.2.4. Corticosteroids
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Topical
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Interleukin Inhibitors
    • 12.2.3. Vitamin D Analogs
    • 12.2.4. Corticosteroids
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Topical
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Psoriasis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Interleukin Inhibitors
    • 13.2.3. Vitamin D Analogs
    • 13.2.4. Corticosteroids
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Topical
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Interleukin Inhibitors
    • 14.2.3. Vitamin D Analogs
    • 14.2.4. Corticosteroids
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Topical
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Amgen, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Strategic Overview
    • 15.3.2. AstraZeneca plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Strategic Overview
    • 15.3.3. AbbVie, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Strategic Overview
    • 15.3.4. Eli Lilly and Company
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Strategic Overview
    • 15.3.5. Johnson & Johnson
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Strategic Overview
    • 15.3.6. Biogen, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Strategic Overview
    • 15.3.7. Novartis AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Strategic Overview
    • 15.3.8. Merck & Co., Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Strategic Overview
    • 15.3.9. Pfizer, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Strategic Overview
    • 15.3.10. LEO Pharma A/S
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Strategic Overview
    • 15.3.11. Other Players

List of Table

  • Table 01: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Psoriasis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 06: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 07: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 10: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 11: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 14: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 22: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Psoriasis Treatment Market Snapshot, 2021
  • Figure 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 04: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021
  • Figure 06: Global Psoriasis Treatment Market Value Share, by Region, 2021
  • Figure 03: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021
  • Figure 05: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021
  • Figure 07: Regulatory Approval Process - U.S.
  • Figure 08: Regulatory Approval Process - Europe
  • Figure 09: Regulatory Approval Process - Japan
  • Figure 10: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 11: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by TNF Inhibitors, 2017-2031
  • Figure 12: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interleukin Inhibitors, 2017-2031
  • Figure 13: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vitamin D Analogs, 2017-2031
  • Figure 14: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017-2031
  • Figure 15: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 16: Global Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 17: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 18: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017-2031
  • Figure 19: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017-2031
  • Figure 20: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2017-2031
  • Figure 21: Global Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 22: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 23: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
  • Figure 24: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
  • Figure 25: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 26: Global Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Global Psoriasis Treatment Market Value Share, by Region, 2021 and 2031
  • Figure 28: Global Psoriasis Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 29: North America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 31: North America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 32: North America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 33: North America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 34: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 35: North America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 37: North America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 38: Europe Psoriasis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 39: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 40: Europe Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 41: Europe Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 42: Europe Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 44: Europe Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 46: Europe Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 47: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 48: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 49: Asia Pacific Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 50: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 51: Asia Pacific Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 52: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 53: Asia Pacific Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 54: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 55: Asia Pacific Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 56: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 57: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 58: Latin America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 59: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 60: Latin America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 61: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 62: Latin America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 63: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 64: Latin America Psoriasis Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 65: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 66: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 68: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 69: Middle East & Africa Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031
  • Figure 70: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 71: Middle East & Africa Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 72: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 73: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031